Eyeworld

JAN 2016

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: http://digital.eyeworld.org/i/618732

Contents of this Issue

Navigation

Page 78 of 78

® © 2014 Novartis 7/14 ILV14057JAD Broad Managed Care Coverage 1 INDICATIONS AND USAGE ILEVRO ® Suspension is a nonsteroidal, anti-in ammatory prodrug indicated for the treatment of pain and in ammation associated with cataract surgery. IMPORTANT SAFETY INFORMATION Contraindications ILEVRO ® Suspension is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other NSAIDs. Warnings and Precautions • Increased Bleeding Time – With some nonsteroidal anti-in ammatory drugs including ILEVRO ® Suspension there exists the potential for increased bleeding time. Ocularly applied nonsteroidal anti-in ammatory drugs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery. • Delayed Healing – Topical nonsteroidal anti-in ammatory drugs (NSAIDs) including ILEVRO ® Suspension may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. • Corneal Effects – Use of topical NSAIDs may result in keratitis. In some patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events. • Contact Lens Wear – ILEVRO ® Suspension should not be administered while using contact lenses. Adverse Reactions The most frequently reported ocular adverse reactions following cataract surgery occurring in approximately 5 to 10% of patients were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. For additional information about ILEVRO ® Suspension, please refer to the brief summary of prescribing information on adjacent page. References: 1. Formulary data provided by Pinsonault Associates, LLC, Pathfi nderRx, June 2014. 2. ILEVRO ® Suspension prescribing information. 3. NEVANAC ® Suspension prescribing information. For more resources for eye care professionals, visit MYALCON.COM/ILEVRO THE NUMBER OF DAILY DOSES DECLINES, BUT THE EFFICACY DOESN'T ILEVRO ® Suspension dosed once daily post-op has been shown to be noninferior to NEVANAC ® (nepafenac ophthalmic suspension) 0.1% dosed three times daily for the resolution of in ammation and pain associated with cataract surgery. 2,3 One drop of ILEVRO ® Suspension should be applied once daily beginning 1 day prior to cataract surgery through 14 days post-surgery, with an additional drop administered 30 to 120 minutes prior to surgery. 2 Use of ILEVRO ® Suspension more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events. 2 Available in 1.7 mL and new 3 mL ll sizes

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - JAN 2016